AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
🇳🇬
Paclitaxel in Nigeria
5 products registered with NAFDAC — 3 active, 2 expired
| Brand / Product | Reg. No. | Holder | Status | Expires |
|---|---|---|---|---|
| Paclitaxel Sandoz 6 mg/mL Concentrate for Solution for Infusion** Solution for infusion | B4-7695 | Novartis Nigeria Limited | active | 24 May 2028 |
| Paclitaxel 100 mg/16.7 mL Concentrate For Solution For Infusion** Concentrate for solution for infusion | A4-100142 | Pfizer Specialties Ltd | active | 1 Dec 2026 |
| Paclitaxel 300 mg/50 mL Concentrate For Solution For Infusion** Concentrate for solution for infusion | A4-100143 | Pfizer Specialties Ltd | active | 1 Dec 2026 |
| PAXUS 30MG INJECTION 1X5ML VIAL | B4-6388 | BOUCIA LIMITED NO. 1 | expired | 1 Jun 2021 |
| PAXUS 100MG INJECTION 1X16.7ML VIAL | B4-6389 | BOUCIA LIMITED NO. 1 | expired | 1 Jun 2021 |
Paclitaxel — NAFDAC Registration Details
NAFDAC (Nigeria) has 5 registered products containing Paclitaxel, of which 3 are currently active. Data is sourced directly from the official NAFDAC drug register and refreshed daily.
Track Paclitaxel registration expiry dates, monitor competitor approvals, and receive alerts when registration status changes. Create a free account to set up portfolio monitoring.